Filing Flows › Phibro Animal Health (PAHC) › Guidance & outlook

Phibro Animal Health (PAHC) guidance and outlook

Phibro Animal Health (PAHC) lowered its guidance on Nov 4, 2026: Revenue $1.6B for FY2027; EBITDA $258M–$268M for FY2027; Net income $140M–$147M for FY2027; Revenue $1.6B for FY2027. Phibro Animal Health's 10-Q filed Nov 4, 2026 makes 18 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

• Production shutdown is expected to be completed in the summer of 2027, and the manufacturing of products made at this facility is expected to be relocated to third party contract manufacturers and our other manufacturing facilities.
• We expect to incur approximately $5.0 million of one-time severance and other employee termination costs in connection with the Chicago Heights closure, which are expected to be paid in the second half of calendar 2027.
• The Company also expects to incur additional costs in connection with the closure, which may include equipment and inventory transfer costs, facility restoration costs, legal and professional fees, and other transition costs.
• All restructuring-related costs will be recognized in our Animal Health segment.
• Management performed a recoverability assessment of the Chicago Heights asset group and determined that the estimated undiscounted future cash flows expected to be generated by the asset group exceeded its carrying amount.
• The Company expects the closure activities to be ongoing through fiscal year 2028.
• We believe global population growth, the growth of the global middle class and the productivity improvements needed due to limitations of arable land and water supplies have supported and will continue to support growth of the animal health industry.
• It is reasonably possible we will resolve a foreign tax audit in a future quarter during this fiscal year that may have a favorable impact on our income tax rate.
• Inventories used $33.9 million of cash due to increased quantities on hand due to timing of inventory purchases and forecasted future demand and the planned buildup of inventory at our Chicago Heights facility before its closure next year, which will enable us to maintain sales of such inventory while we transition production to third party manufacturers and other of our manufacturing facilities.
• We believe our cash on hand, operating cash flows and financing arrangements, including the availability of borrowings under our credit facility, will be sufficient to support our ongoing cash needs.
• At this time, we expect adequate liquidity for at least the next twelve months.
• We can provide no assurance that our liquidity and capital resources will be adequate for future funding requirements.

Phibro Animal Health's latest quarter

Questions

Did Phibro Animal Health raise or lower its guidance?

Phibro Animal Health (PAHC) lowered its guidance on Nov 4, 2026: Revenue $1.6B for FY2027; EBITDA $258M–$268M for FY2027; Net income $140M–$147M for FY2027; Revenue $1.6B for FY2027.

What does Phibro Animal Health expect?

Production shutdown is expected to be completed in the summer of 2027, and the manufacturing of products made at this facility is expected to be relocated to third party contract manufacturers and our other manufacturing facilities. We expect to incur approximately $5.0 million of one-time severance and other employee termination costs in connection with the Chicago Heights closure, which are expected to be paid in the second half of calendar 2027. The Company also expects to incur additional costs in connection with the closure, which may include equipment and inventory transfer costs, facili

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.